Hottest Stocks (Over $10)	Hottest Stocks ($2-$10)	Biggest Losers (Over $10)	Biggest Losers ($2-$10)	Hottest Industries	Hottest Sectors	EPS / Sales Surprises
Enter Ticker Symbol:   Ticker Lookup Company Quote Company Profile Research Summary EPS Consensus Perspective Insider Transactions Price Performance

Enter any portion of the company’s name to find its corresponding ticker symbol:

Search for :

Zacks Company Profile for Coherus Oncology, Inc. (CHRS : NSDQ)

• Company Description    Coherus is a fully integrated commercial-stage innovative oncology company. Coherus, formerly known as Coherus BioSciences Inc., is based in REDWOOD CITY, Calif. Number of Employees: 147

• Price / Volume Information    Yesterday's Closing Price: $1.02 Daily Weekly Monthly 20 Day Moving Average: 1,467,906 shares Shares Outstanding: 154.50 (millions) Market Capitalization: $157.59 (millions) Beta: 0.98 52 Week High: $1.31 52 Week Low: $0.55 Short Interest Ratio:   % Price Change % Price Change Relative to S&P 500 4 Week -19.05% -19.58% 12 Week -27.66% -31.77% Year To Date -28.17% -36.61%

• Address & Contact Information Street Address Phone / Fax Email Address Web URL 333 TWIN DOLPHIN DRIVE SUITE 600 - REDWOOD CITY,CA 94065 USA ph: 650-649-3530 fax: - ir@coherus.com http://www.coherus.com

• General Corporate Information    Officers Dennis M. Lanfear - Chief Executive Officer; Chairman and President Bryan McMichael - Chief Financial Officer Georgia Erbez - Director Lee N. Newcomer - Director Charles W. Newton - Director Peer Information Coherus Oncology, Inc. (CORR.) Coherus Oncology, Inc. (RSPI) Coherus Oncology, Inc. (CGXP) Coherus Oncology, Inc. (BGEN) Coherus Oncology, Inc. (GTBP) Coherus Oncology, Inc. (RGRX) Industry / Sector / Ticker Info Analyst Coverage: No Industry Group: MED-BIOMED/GENE Sector: Medical CUSIP: 19249H103 SIC: 2836 Fiscal Year Fiscal Year End: December Last Reported Quarter: 06/01/26 Next Expected EPS Date: 11/05/26 Share - Related Items Shares Outstanding: 154.50 Most Recent Split Date: (:1) Beta: 0.98 Market Capitalization: $157.59 (millions)

• EPS Information     • Dividend Information Analyst Coverage: No Dividend Yield: 0.00% Current Fiscal Quarter EPS Consensus Estimate: $-0.21 Indicated Annual Dividend: $0.00 Current Fiscal Year EPS Consensus Estimate: $-0.88 Payout Ratio: Number of Estimates in the Fiscal Year Consensus: 3.00 Change In Payout Ratio: Estmated Long-Term EPS Growth Rate: % Last Dividend Paid: NA - $0.00 Next EPS Report Date: 11/05/26

• Fundamental Ratios P/E Current FY Estimate: - Trailing 12 Months: - PEG Ratio: - Price Ratios Price/Book: 2.59 Price/Cash Flow: - Price / Sales: 3.09 EPS Growth vs. Year Ago Period: 43.59% vs. Previous Quarter: 18.52% Sales Growth vs. Year Ago Period: 39.53% vs. Previous Quarter: 16.22% ROE 09/30/26 - - 06/30/26 - -222.75 03/31/26 - -198.90 ROA 09/30/26 - - 06/30/26 - -52.11 03/31/26 - -46.65 Current Ratio 09/30/26 - - 06/30/26 - 1.77 03/31/26 - 1.56 Quick Ratio 09/30/26 - - 06/30/26 - 1.70 03/31/26 - 1.52 Operating Margin 09/30/26 - - 06/30/26 - -315.14 03/31/26 - -368.28 Net Margin 09/30/26 - - 06/30/26 - -259.41 03/31/26 - 397.30 Pre-Tax Margin 09/30/26 - - 06/30/26 - -316.37 03/31/26 - -368.28 Book Value 09/30/26 - - 06/30/26 - 0.39 03/31/26 - 0.51 Inventory Turnover 09/30/26 - - 06/30/26 - 4.03 03/31/26 - 4.11 Debt-to-Equity 09/30/26 - - 06/30/26 - 0.61 03/31/26 - 0.47 Debt-to-Capital 09/30/26 - - 06/30/26 - 37.97 03/31/26 - 32.09

Powered by Zacks Investment Research ©